文献速递系统性红斑狼疮其他结缔组织病

MFG-E8通过结合αv整合素抑制潜在TGFβ诱导的纤维化及其在系统性硬化症皮肤纤维化中的作用

Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2019-01-04

本研究探讨MFG-E8在系统性硬化症(SSc)皮肤纤维化中的作用。SSc患者皮肤血管周围MFG-E8表达及血清MFG-E8水平低于健康人;重组MFG-E8可抑制SSc成纤维细胞中潜在TGFβ诱导的I型胶原、α-SMA和CCN2表达;MFG-E8缺陷加重小鼠肺和皮肤纤维化,而给予重组MFG-E8可抑制博来霉素诱导的皮肤纤维化。提示MFG-E8对潜在TGFβ诱导的皮肤纤维化负调控不足可能参与SSc发病,并可能成为治疗靶点。

要点

  • SSc患者皮肤血管周围MFG-E8表达及血清MFG-E8水平低于健康人。
  • 重组MFG-E8抑制SSc成纤维细胞中潜在TGFβ诱导的I型胶原、α-SMA和CCN2表达。
  • MFG-E8缺陷加重小鼠肺和皮肤纤维化,给予重组MFG-E8抑制博来霉素诱导的皮肤纤维化。

核心结论

  • MFG-E8通过结合αv整合素抑制潜在TGFβ活化及TGFβ信号,从而负调控皮肤纤维化。
  • SSc中MFG-E8表达降低导致对潜在TGFβ诱导的皮肤纤维化抑制不足,可能参与SSc发病,并可能成为纤维化治疗靶点。

研究设计与样本

  • 评估SSc患者皮肤和血清MFG-E8表达,并检测重组MFG-E8对SSc成纤维细胞的作用。
  • 使用MFG-E8缺陷或给药的小鼠纤维化模型(博来霉素诱导模型和TSK小鼠模型)。

主要发现

  • SSc患者皮肤血管周围MFG-E8表达(n=7)和血清MFG-E8水平(n=44)低于健康人(n=6和n=28)。
  • 重组MFG-E8显著抑制SSc成纤维细胞(n=3-8)中潜在TGFβ诱导的I型胶原、α-SMA和CCN2表达。
  • 在博来霉素诱导纤维化小鼠(n=5-8)和TSK小鼠(n=5-10)中,MFG-E8缺陷显著加重肺和皮肤纤维化。
  • 给予重组MFG-E8显著抑制博来霉素诱导的皮肤纤维化。

临床怎么用

  • MFG-E8可能作为SSc皮肤纤维化的潜在治疗靶点,但需进一步临床研究验证。

局限性

  • SSc患者皮肤和血清样本量较小(n=7和n=44)。
  • 机制研究主要基于体外细胞和小鼠模型,尚未在人体中验证治疗价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Several studies have demonstrated that the secreted glycoprotein and integrin ligand milk fat globule-associated protein with epidermal growth factor- and factor VIII-like domains (MFG-E8) negatively regulates fibrosis in the liver, lungs, and respiratory tract. However, the mechanisms and roles of MFG-E8 in skin fibrosis in systemic sclerosis (SSc) have not been characterized. We undertook this study to elucidate the role of MFG-E8 in skin fibrosis in SSc. METHODS: We assessed expression of MFG-E8 in the skin and serum in SSc patients. We examined the effect of recombinant MFG-E8 (rMFG-E8) on latent transforming growth factor β (TGFβ)-induced gene/protein expression in SSc fibroblasts. We examined the effects of deficiency or administration of MFG-E8 on fibrosis mouse models. RESULTS: We demonstrated that MFG-E8 expression around dermal blood vessels and the serum MFG-E8 level in SSc patients (n = 7 and n = 44, respectively) were lower than those in healthy individuals (n = 6 and n = 28, respectively). Treatment with rMFG-E8 significantly inhibited latent TGFβ-induced expression of type I collagen, α-smooth muscle actin, and CCN2 in SSc fibroblasts (n = 3-8), which suggested that MFG-E8 inhibited activation of latent TGFβ as well as TGFβ signaling via binding to αv integrin. In a mouse model of bleomycin-induced fibrosis (n = 5-8) and in a TSK mouse model (a genetic model of SSc) (n = 5-10), deficient expression of MFG-E8 significantly enhanced both pulmonary and skin fibrosis, and administration of rMFG-E8 significantly inhibited bleomycin-induced dermal fibrosis. CONCLUSION: These results suggest that vasculopathy-induced dysfunction of pericytes and endothelial cells, the main cells secreting MFG-E8, may be associated with the decreased expression of MFG-E8 in SSc and that the deficient inhibitory regulation of latent TGFβ-induced skin fibrosis by MFG-E8 may be involved in the pathogenesis of SSc and may be a therapeutic target for fibrosis in SSc patients.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fujiwara C, Uehara A, Sekiguchi A, et al. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 30175895. doi:10.1002/art.40701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。